Adoptive Cell Therapy Across Cancer Diagnoses

Only patients within the Danish Healthcare system are eligible for enrollment.

Inclusion Criteria:

* Histologically verified metastatic or locally advanced cancer diagnosis
* At least one lesion (\>1 cm3) available for surgical resection
* Not candidate for standard treatment options
* Age of 18-70 years
* Performance status of 1 or 0.
* Life expectancy \> 6 months
* One or more measurable parameter according to RECIST 1.1.
* No significant toxicity from previous cancer treatments (CTC≤1). Except alopecia (CTC≤2) or neuropathy (CTC≤2)
* Sufficient organ function, including:
* Absolute neutrophil count (ANC) ≥ 1.500 /µl
* Leucocyte count ≥ normal limit
* Platelets ≥ 100.000 /µl and \<700.000 /µl
* Hemoglobin ≥ 6,0 mmol/l (regardless of prior transfusion)
* S-creatinine \< 140
* S-bilirubin ≤ 1,5 times upper normal limit
* ASAT/ALAT ≤ 2,5 times upper normal limit
* Alkaline phosphatase ≤ 5 times upper normal limit
* Lactate dehydrogenase (LDH) ≤ 5 times upper normal limit
* Sufficient coagulation: PP-time\>40 and INR\<1,5
* Women in the fertile age must use effective contraception. This applies from inclusion and until 6 months after treatment. Birth control pills, spiral, depot injection with gestagen, subdermal implantation, hormonal vaginal ring and transdermal depot patch are all considered safe contraceptives.
* Signed statement of consent after receiving oral and written study information
* Willingness to participate in the planned treatment and follow-up and capable of handling toxicities.

Exclusion Criteria:

* A history of prior malignancies. Patients treated for another malignancy can only participate if they are without signs of disease for a minimum of 3 years after last treatment.
* Primary brain tumor or verified brain metastases
* Known hypersensitivity to one of the active drugs or excipients.
* Significant medical conditions, including but not limited to severe asthma/COLD, significant cardiac disease, poorly regulated insulin dependent diabetes mellitus.
* Creatinine clearance below 70 ml/min .
* Acute or chronic infections with HIV, hepatitis, syphilis etc.
* Severe allergies or previous anaphylactic reactions.
* Active autoimmune disease, such as autoimmune neutropenia/thrombocytopenia or hemolytic anemia, systemic lupus erythematosus, Sjögren's syndrome, sclerodermia, myasthenia gravis, goodpastures disease, addison's disease, hashimoto's thyroiditis, graves' disease etc.
* Pregnant women and women who are breastfeeding.
* Simultaneous treatment with systemic immunosuppressive drugs (including prednisolone methotrexate etc.)
* Simultaneous treatment with other experimental drugs.
* Simultaneous treatment with other systemic anti-cancer treatments.
* Patients with active or uncontrollable hypercalcemia.